Insight Molecular Diagnostics Inc. (IMDX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2 International Plaza Dr.
Nashville, TN 37217
United States of America (the)
Phone
949 409 7600
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
57
First IPO Date
December 30, 2015
| Name | Title | Pay | Year Born |
| Joshua Riggs | President, Chief Executive Officer & Director | 662,787 | 1983 |
| Michael D. West | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | 0 | 1953 |
| James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer | 303,253 | 1996 |
| Andrea Susan James | Chief Financial Officer | 536,578 | 1982 |
| Ekkehard Schutz | Chief Science Officer | 552,014 | N/A |
| Yuh-Min Chiang | Chief Technology Officer | 0 | N/A |
| Steven Tahmooressi | Vice President of Marketing | 0 | N/A |
| Sandra O'Donald | Senior Vice President of Business Operations | 0 | N/A |
| Peter Hong | Vice President, General Counsel & Secretary | 0 | N/A |
| Paul R. Billings FACP | Consulting Chief Medical Officer | 0 | 1952 |
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.